Epidemiological Trends and Survival Outcomes for Thymic Epithelial Tumours: An Australian Population-Based Retrospective Cohort Study.

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation Pub Date : 2025-05-15 DOI:10.1016/j.hlc.2024.12.011

Joshua G Goldblatt, Lachlan P Crawford, Danica Cossio, Christopher M W Cole

{"title":"Epidemiological Trends and Survival Outcomes for Thymic Epithelial Tumours: An Australian Population-Based Retrospective Cohort Study.","authors":"Joshua G Goldblatt, Lachlan P Crawford, Danica Cossio, Christopher M W Cole","doi":"10.1016/j.hlc.2024.12.011","DOIUrl":null,"url":null,"abstract":"Background: Thymic epithelial tumours (TETs) represent a heterogenous group of relatively uncommon lesions which have varied disease behaviour. There is limited literature on the epidemiology and survival outcomes of these tumours in an Australian context.Method: We conducted a population-based retrospective cohort study of patients diagnosed with TETs in the Australian state of Queensland between 2000 and 2021, recruited via the Queensland Oncology Repository.Results: Four hundred and ninety-seven (497) patients were identified, with a significant increase in the incidence of TETs over the study period. The 5-year overall survival for the full study cohort was 80.7%, declining to 67.1% at 10 years. Disease-specific survival was higher at 87.1% by 5 years, and 79.3% at 10 years. The majority of patients underwent upfront surgical resection, with a trend towards better survival.Conclusions: Survival outcomes to 5 years and beyond are generally favourable, particularly for patients with less histologically aggressive lesions. Patients treated surgically, either with or without neoadjuvant chemotherapy/radiotherapy, had favourable survival and disease control compared to patients receiving definitive intent chemotherapy and/or radiotherapy.","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart, Lung and Circulation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.hlc.2024.12.011","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Thymic epithelial tumours (TETs) represent a heterogenous group of relatively uncommon lesions which have varied disease behaviour. There is limited literature on the epidemiology and survival outcomes of these tumours in an Australian context.

Method: We conducted a population-based retrospective cohort study of patients diagnosed with TETs in the Australian state of Queensland between 2000 and 2021, recruited via the Queensland Oncology Repository.

Results: Four hundred and ninety-seven (497) patients were identified, with a significant increase in the incidence of TETs over the study period. The 5-year overall survival for the full study cohort was 80.7%, declining to 67.1% at 10 years. Disease-specific survival was higher at 87.1% by 5 years, and 79.3% at 10 years. The majority of patients underwent upfront surgical resection, with a trend towards better survival.

Conclusions: Survival outcomes to 5 years and beyond are generally favourable, particularly for patients with less histologically aggressive lesions. Patients treated surgically, either with or without neoadjuvant chemotherapy/radiotherapy, had favourable survival and disease control compared to patients receiving definitive intent chemotherapy and/or radiotherapy.

查看原文本刊更多论文

胸腺上皮肿瘤的流行病学趋势和生存结果：一项基于澳大利亚人群的回顾性队列研究。

背景：胸腺上皮肿瘤（TETs）代表了一组异质性的相对罕见的病变，具有不同的疾病行为。在澳大利亚，关于这些肿瘤的流行病学和生存结果的文献有限。方法：我们对2000年至2021年间在澳大利亚昆士兰州诊断为tet的患者进行了一项基于人群的回顾性队列研究，这些患者通过昆士兰州肿瘤学知识库招募。结果：497（497）名患者被确定，在研究期间，tet的发病率显著增加。整个研究队列的5年总生存率为80.7%，10年后降至67.1%。5年和10年的疾病特异性生存率分别为87.1%和79.3%。大多数患者接受了前期手术切除，生存率有提高的趋势。结论：5年及以上的生存结果通常是有利的，特别是对于组织学侵袭性较小的患者。与接受明确意向化疗和/或放疗的患者相比，接受手术治疗的患者，无论是否接受新辅助化疗/放疗，都有较好的生存期和疾病控制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Heart, Lung and Circulation CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

4.50

自引率

3.80%

发文量

912

审稿时长

11.9 weeks

期刊介绍： Heart, Lung and Circulation publishes articles integrating clinical and research activities in the fields of basic cardiovascular science, clinical cardiology and cardiac surgery, with a focus on emerging issues in cardiovascular disease. The journal promotes multidisciplinary dialogue between cardiologists, cardiothoracic surgeons, cardio-pulmonary physicians and cardiovascular scientists.